| PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison… | Aroda VR | Diabetes Care | 2019 | Journal article | 6 |
| RoB 2: a revised tool for assessing risk of bias in randomised trials | Sterne JAC | BMJ | 2019 | Journal article | 11 |
| Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony… | Hernandez AF | The Lancet | 2018 | Journal article | 0 |
| LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from… | Coskun T | Molecular Metabolism | 2018 | Journal article | 10 |
| Mechanisms of action and therapeutic application of glucagon-like peptide-1 | Drucker DJ | Cell Metabolism | 2018 | Journal article | 39 |
| Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data | Pickart L | International Journal of Molecular Sciences | 2018 | Journal article | 3 |
| Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised… | Pratley RE | The Lancet Diabetes & Endocrinology | 2018 | Journal article | 6 |
| Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species | Jensen L | European Journal of Pharmaceutical Sciences | 2017 | Journal article | 1 |
| Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes | Holman RR | New England Journal of Medicine | 2017 | Journal article | 7 |
| Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes… | Sorli C | The Lancet Diabetes & Endocrinology | 2017 | Journal article | 0 |
| ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories | International Organization for Standardization | ISO/IEC Standard | 2017 | Guideline | 8 |
| Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled… | Clayton AH | Women’s Health | 2016 | Journal article | 11 |
| Liraglutide and cardiovascular outcomes in type 2 diabetes | Marso SP | New England Journal of Medicine | 2016 | Journal article | 10 |
| Semaglutide and cardiovascular outcomes in patients with type 2 diabetes | Marso SP | New England Journal of Medicine | 2016 | Journal article | 3 |
| A randomized, controlled trial of 3.0 mg of liraglutide in weight management | Pi-Sunyer X | New England Journal of Medicine | 2015 | Journal article | 10 |
| Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide | Lau J | Journal of Medicinal Chemistry | 2015 | Journal article | 7 |
| Lixisenatide in patients with type 2 diabetes and acute coronary syndrome | Pfeffer MA | New England Journal of Medicine | 2015 | Journal article | 6 |
| The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin… | Lee C | Cell Metabolism | 2015 | Journal article | 3 |
| First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics | Szeto HH | British Journal of Pharmacology | 2014 | Journal article | 4 |
| Related impurities in peptide medicines | D’Hondt M | Journal of Pharmaceutical and Biomedical… | 2014 | Journal article | 70 |
| Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only —… | United States Food and Drug Administration | FDA Guidance | 2013 | Regulatory document | 0 |
| Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications | Goldstein AL | Expert Opinion on Biological Therapy | 2012 | Journal article | 5 |
| GRADE guidelines: 3. Rating the quality of evidence | Balshem H | Journal of Clinical Epidemiology | 2011 | Journal article | 0 |
| GRADE guidelines: 6. Rating the quality of evidence — imprecision | Guyatt GH | Journal of Clinical Epidemiology | 2011 | Journal article | 3 |
| GRADE guidelines: 8. Rating the quality of evidence — indirectness | Guyatt GH | Journal of Clinical Epidemiology | 2011 | Journal article | 3 |
| Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract | Sikiric P | Current Pharmaceutical Design | 2011 | Journal article | 1 |
| Protein aggregation — pathways and influencing factors | Wang W | International Journal of Pharmaceutics | 2010 | Journal article | 13 |
| Stability of protein pharmaceuticals: an update | Manning MC | Pharmaceutical Research | 2010 | Journal article | 58 |
| Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised… | Buse JB | The Lancet | 2009 | Journal article | 15 |
| GRADE: an emerging consensus on rating quality of evidence and strength of recommendations | Guyatt GH | BMJ | 2008 | Journal article | 0 |
| HPLC analysis and purification of peptides | Mant CT | Methods in Molecular Biology | 2007 | Journal article | 4 |
| Metabolic effects of a growth hormone-releasing factor in patients with HIV | Falutz J | New England Journal of Medicine | 2007 | Journal article | 8 |
| Thymosin α1 and cancer: action on immune effector and tumor target cells | Garaci E | Annals of the New York Academy of Sciences | 2007 | Journal article | 4 |
| Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a… | Teichman SL | Journal of Clinical Endocrinology & Metabolism | 2006 | Journal article | 11 |
| ICH Q1A(R2) Stability Testing of New Drug Substances and Products | International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use | ICH Harmonised Tripartite Guideline | 2003 | Guideline | 8 |
| Measuring inconsistency in meta-analyses | Higgins JPT | BMJ | 2003 | Journal article | 4 |
| Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with… | Hollander PA | Diabetes Care | 2003 | Journal article | 5 |
| The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment… | Heffernan M | Endocrinology | 2001 | Journal article | 1 |
| Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily… | Knudsen LB | Journal of Medicinal Chemistry | 2000 | Journal article | 8 |
| ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products | International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use | ICH Harmonised Tripartite Guideline | 1999 | Guideline | 24 |